Investment-Driven Breakthroughs Put Cancer and Chronic Disease in Focus

Decades of biomedical investment are yielding notable advances, including a pancreatic cancer therapy that doubles survival in late-stage trials, an obesity drug with powerful weight loss, and early Gene-editing approaches that could lower disease risk; while these advances extend life and hint at cures, high costs and access barriers persist, underscoring the need for sustained funding and a stronger emphasis on prevention.